Literature DB >> 8644811

Improvement in subjective visual function and quality of life outcome measures after blepharoptosis surgery.

V K Battu1, D R Meyer, J L Wobig.   

Abstract

PURPOSE: To examine patients' subjective perception of visual function and health-related quality of life as affected by blepharoptosis and the change in these perceptions after blepharoptosis surgery.
METHODS: A 27-item questionnaire pertaining to vision-related activities and symptoms was used preoperatively to assess 50 consecutive patients (18 years old or older) with unilateral or bilateral acquired involutional blepharoptosis, and postoperatively six to eight weeks after blepharoptosis repair.
RESULTS: Of the 24 items statistically analyzed, 16 items (67%) demonstrated significant improvement postoperatively (P < .05) among the unilateral cases and 18 items (75%) showed significant improvement postoperatively (P < .05) among the bilateral cases. The four activities that improved the most after surgery for both the unilateral and bilateral groups were the ability to perform fine manual work, hanging or reaching objects above eye level, watching television, and reading.
CONCLUSIONS: Surgical repair of acquired involutional blepharoptosis resulted in significant improvement in several aspects of patients' subjective visual function and health-related quality of life. These issues are important in determining both the indications for and outcome of blepharoptosis surgery.

Entities:  

Mesh:

Year:  1996        PMID: 8644811     DOI: 10.1016/s0002-9394(14)70634-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  19 in total

1.  Brow ptosis: are we measuring the right thing? The impact of surgery and the correlation of objective and subjective measures with postoperative improvement in quality-of-life.

Authors:  F Mellington; R Khooshabeh
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

2.  Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?

Authors:  M E McClure; P M Hart; A J Jackson; M R Stevenson; U Chakravarthy
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

3.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

4.  Effects of upper lid blepharoplasty on visual quality in patients with lash ptosis and dermatochalasis.

Authors:  Seoung Hyun An; Sang Wook Jin; Yoon Hyung Kwon; Won Yeol Ryu; Woo Jin Jeong; Hee Bae Ahn
Journal:  Int J Ophthalmol       Date:  2016-09-18       Impact factor: 1.779

5.  A vision specific functional index for use in patients with age related macular degeneration.

Authors:  P M Hart; U Chakravarthy; M R Stevenson; J Q Jamison
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

6.  Prevalence and associated factors of blepharoptosis in Korean adult population: The Korea National Health and Nutrition Examination Survey 2008-2011.

Authors:  M H Kim; J Cho; D Zhao; K I Woo; Y-D Kim; S Kim; S W Yang
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

7.  Correlation of quality of life with clinical symptoms and signs at the time of glaucoma diagnosis.

Authors:  R P Mills
Journal:  Trans Am Ophthalmol Soc       Date:  1998

8.  Psychosocial implications of blepharoptosis and dermatochalasis.

Authors:  J D Bullock; R E Warwar; D G Bienenfeld; S L Marciniszyn; R J Markert
Journal:  Trans Am Ophthalmol Soc       Date:  2001

9.  Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL.

Authors:  C B Terwee; M N Gerding; F W Dekker; M F Prummel; W M Wiersinga
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

10.  Association of Upper Eyelid Ptosis Repair and Blepharoplasty With Headache-Related Quality of Life.

Authors:  Ilke Bahceci Simsek
Journal:  JAMA Facial Plast Surg       Date:  2017-07-01       Impact factor: 4.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.